NEW YORK (GenomeWeb) – Miragen Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, has completed its merger with molecular diagnostics company Signal Genetics.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.